Results From the Periodontitis and Vascular Events (PAVE) Study: A Pilot Multicentered Randomized Controlled Trial to Study Effects of Periodontal Therapy in a Secondary Prevention Model of Cardiovascular Disease

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

David A. Barrow (Creator)

James D. Beck (Creator)

David J. Couper (Creator)

Karen L. Falkner (Creator)

Robert J. Genco (Creator)

Susan P. Graham (Creator)

Sara Grossi (Creator)

John C. Gunsolley (Creator)

Theresa Madden (Creator)

Gerardo Maupome (Creator)

Luisito Mendoza (Creator)

Kevin Moss (Creator)

Steven Offenbacher (Creator)

David W. Paquette (Creator)

Dawn D. Steward (Creator)

Maurizio Trevisan (Creator)

Dyke Thomas E. Van (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Background- In the Periodontitis and Vascular Events (PAVE) pilot study periodontal therapy was provided as an intervention in a secondary cardiac event prevention model through five coordinated cardiac-dental centers. Methods- Subjects were randomized to either community care or protocol provided scaling and root planing to evaluate effects on periodontal status and systemic levels of high-sensitivity Creactive protein (hs-CRP). Results- After 6 months there was a significant reduction in mean probing depth and extent of 4- or 5-mm pockets. However there were no significant differences in attachment levels bleeding upon probing or extent of subgingival calculus comparing subjects assigned to protocol therapy (n = 151) to those assigned to community care (n = 152). Using intent-to-treat analyses there was no significant effect on serum hs-CRP levels at 6 months. However 48% of the subjects randomized to community care received preventive or periodontal treatments. Secondary analyses demonstrated that consideration of any preventive or periodontal care (i.e. any treatment) compared to no treatment showed a significant reduction in the percentage of people with elevated hs-CRP (values >3 mg/l)at 6 months. However obesity nullified the periodontal treatment effects on hs-CRP reduction. The adjusted odds ratio for hs-CRP levels >3 mg/l at 6 months for any treatment versus no treatment among non-obese individuals was 0.26 (95%confidence interval: 0.09 to 0.72) adjusting for smoking marital status and gender. Conclusion- This pilot study demonstrated the critical role of considering obesity as well as rigorous preventive and periodontal care in trials designed to reduce cardiovascular risk. Originally published Journal of Periodontology Vol. 80 No. 2 Feb 2009

Additional Information

Publication

Other

Journal of Periodontology. 80:2(February 2009) p. 190-201.

Language: English

Date: 2011

Keywords

C-reactive protein, cardiovascular diseases, controlled clinical trial, Obesity, periodontitis, prevention

Email this document to